These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 7595747)

  • 41. Phase II studies of pemetrexed in metastatic breast and gynecologic cancers.
    Smith I
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):63-5. PubMed ID: 15655940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.
    Clarke SJ; Hanwell J; de Boer M; Planting A; Verweij J; Walker M; Smith R; Jackman AL; Hughes LR; Harrap KR; Kennealey GT; Judson IR
    J Clin Oncol; 1996 May; 14(5):1495-503. PubMed ID: 8622063
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
    Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
    Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.
    Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J; Norris J; Matsushita H; Mita A; Rowinsky EK
    Invest New Drugs; 2012 Feb; 30(1):316-26. PubMed ID: 20839029
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia.
    Abdel-Karim I; Plunkett WK; O'Brien S; Giles F; Thomas D; Faderl S; Ravandi F; Rios MB; Du M; Schneck KB; Chen VJ; Lin BK; Nicol SJ; Kantarjian HM
    Invest New Drugs; 2011 Apr; 29(2):323-31. PubMed ID: 20091088
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer.
    Sweeney CJ; Takimoto CH; Latz JE; Baker SD; Murry DJ; Krull JH; Fife K; Battiato L; Cleverly A; Chaudhary AK; Chaudhuri T; Sandler A; Mita AC; Rowinsky EK
    Clin Cancer Res; 2006 Jan; 12(2):536-42. PubMed ID: 16428497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
    Dy GK; Suri A; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Atherton PJ; Hanson LJ; Burch PA; Rubin J; Erlichman C; Adjei AA
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):522-30. PubMed ID: 15754203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
    Eckhardt SG; Baker SD; Britten CD; Hidalgo M; Siu L; Hammond LA; Villalona-Calero MA; Felton S; Drengler R; Kuhn JG; Clark GM; Smith SL; MacDonald JR; Smith C; Moczygemba J; Weitman S; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 2000 Dec; 18(24):4086-97. PubMed ID: 11118470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pemetrexed in gastric cancer: clinical experience and future perspectives.
    Celio L; Buzzoni R; Longarini R; Marchianò A; Bajetta E
    Semin Oncol; 2002 Dec; 29(6 Suppl 18):63-8. PubMed ID: 12571814
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
    Adjei AA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.
    Rowinsky EK; Noe DA; Grochow LB; Sartorious SE; Bowling MK; Chen TL; Lubejko BG; Kaufmann SH; Donehower RC
    J Clin Oncol; 1995 Aug; 13(8):1975-84. PubMed ID: 7636538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
    Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
    Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL
    J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.
    Rowinsky EK; Beeram M; Hammond LA; Schwartz G; De Bono J; Forouzesh B; Chu Q; Latz JE; Hong S; John W; Nguyen B
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):532-9. PubMed ID: 17255275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.